Rabies Vaccine Market to Reach $ 1903.17 million by 2032, exhibiting a CAGR of 4.7% from 2023 to 2032: Allied Market Research

Rise in prevalence of rabies in developing countries, increase in number of dog bites and rising number of stray dogs and presence of large market players who manufactures rabies vaccine is anticipated to boost the growth of rabies vaccine market. Moreover, rise in awareness among the population regarding importance of vaccination and increase in number of post-exposure prophylaxis is anticipated to drive the growth of the global rabies vaccine market.

PORTLAND, Ore., Nov. 25, 2023 /PRNewswire/ — Allied Market Research published a report, titled, “Rabies vaccine Market by Type (Chick Embryo Cells Rabies Vaccine, Vero Cell Rabies Vaccine, Human Diploid Cell Vaccine and Others), Prophylaxis Type (Pre-Exposure Prophylaxis and Post Exposure Prophylaxis), Application (Human and Animal) and End User (Hospitals, Veterinary Clinics, and Others): Global Opportunity Analysis and Industry Forecast, 2023-2032″. According to the report, the global rabies vaccine market was valued for $1,207.03 million in 2022, and is projected to reach $1,903.17 million by 2032, registering a CAGR of 4.7% from 2023 to 2032.

Request Sample of the Report on Rabies Vaccine Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/3264

Prime determinants of growth

Rise in prevalence of rabies, increase in post exposure prophylaxis for rabies and increase in number of initiatives by government for eradication rabies is anticipated to boost the growth of market. However, high cost of rabies vaccine is anticipated to hinder the growth of market. On the contrary, high presence of rabies vaccine providers, rise in number of adoptions of key strategies by manufacturers of rabies vaccine is to witness growth during the forecast period.

Report coverage & details:

Report Coverage	Details
Forecast Period	2023–2032
Base Year	2022
Market Size in 2022	$1,207.03 million
Market Size in 2032	$1,903.17 million
CAGR	4.7 %
No. of Pages in Report	451
Segments covered	Type, Prophylaxis Type Application, End User and Region.
Drivers	Rise in prevalence of rabies in developing countries High presence of rabies vaccine manufacturers
Opportunities	Rise in adoption of number of strategies by market players of rabies vaccine
Restraints	High cost of rabies vaccine

Want to Explore More, Connect to our Analyst- https://www.alliedmarketresearch.com/connect-to-analyst/3264

The chick embryo cells rabies vaccine segment to maintain its leadership status throughout the forecast period

By product type, the chick embryo cells rabies vaccine segment held the highest market share in 2022, accounting for nearly two-fifth of the global rabies vaccine market revenue and is estimated to maintain its leadership status throughout the forecast period, owing to the high presence of market players who manufactures chick embryo cells rabies vaccine. However, the human diploid cell vaccine segment is projected to manifest significant growth with a CAGR of 5.3% from 2023 to 2032, owing to the effectiveness and safety associated to human diploid cell vaccine.

The post exposure prophylaxis segment to maintain its leadership status throughout the forecast period

By prophylaxis type, the post exposure prophylaxis segment held the highest market share in 2022, accounting for more than three-fifth of the global rabies vaccine market revenue and is estimated to maintain its leadership status throughout the forecast period, owing to rise in awareness among population regarding post-exposure prophylaxis. However, the pre-exposure prophylaxis segment is projected to manifest a significant CAGR of 5.1% from 2023 to 2032, owing to rise in number of pre exposure prophylaxis by tourist, healthcare activist, environmentalist and population who are having pets.

The human segment to maintain its leadership status throughout the forecast period

By application, the human segment held the highest market share in 2022, accounting for more than three-fifth of the global rabies vaccine market revenue and is estimated to maintain its leadership status throughout the forecast period, owing to rise in awareness among the population regarding importance of vaccination. However, the animal segment is projected to manifest a significant CAGR of 5.0% from 2023 to 2032.

The hospitals segment to maintain its leadership status throughout the forecast period

By end user, the hospitals segment held the highest market share in 2022, accounting for more than two-fifth of the global rabies vaccine market revenue and is estimated to maintain its leadership status throughout the forecast period, owing to rise in number of vaccinations in hospitals. However, the veterinary clinics segment is projected to manifest a significant CAGR of 5.2% from 2023 to 2032.

For Procurement Information- https://www.alliedmarketresearch.com/purchase-enquiry/3264

North America to maintain its dominance by 2032

By region, North America held the highest market share in terms of revenue in 2022, accounting for more than one-third of the global rabies vaccine market revenue. This is attributed to high presence of rabies vaccine manufacturers in North America and rising number of initiatives taken by government for animal vaccination. However, the Asia-Pacific region is expected to witness the fastest CAGR of 5.2% from 2023 to 2032 and is likely to dominate the market during the forecast period, owing to increase in awareness among the population regarding importance of rabies vaccination, rise in number of dog bites and increase in number of stray dogs in developing countries like India.

Leading Market Players:

Bharat Biotech International Limited
Sanofi
Boehringer Ingelheim International Gmbh
Novartis Ag
Cadila Pharmaceuticals Ltd
Merck And Co., Inc.
Serum Institute of India Pvt. Ltd.
Zoetis Inc.
Elanco Animal Health Incorporated.
Virbac Sa

The report provides a detailed analysis of these key players of the global rabies vaccine market. These players have adopted different strategies such as agreement, partnership, acquisition, and business expansion to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.

Comprehensive Healthcare Industry Research Studies:

mHealth Market – Global Opportunity Analysis and Industry Forecast, 2022–2032

Biomaterials Market – Global Opportunity Analysis and Industry Forecast, 2022–2032

Flow Cytometry Market- Global Opportunity Analysis and Industry Forecast, 2022–2032

Healthcare IT Market – Global Opportunity Analysis and Industry Forecast, 2022–2032

MRI System Market- Global Opportunity Analysis and Industry Forecast, 2022–2032

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact

David Correa

1209 Orange Street,

Corporation Trust Center,

Wilmington, New Castle,

Delaware 19801 USA.

Toll Free: +1-800-792-5285

Int’l: +1-503-894-6022

UK: +44-845-528-1300

Hong Kong: +852-301-84916

India (Pune): +91-20-66346060

Fax: +1-855-550-5975

[email protected]

Web: https://www.alliedmarketresearch.com

Follow Us on: LinkedIn